Caregiver’s Guide: Supporting a Loved One on Medical Cannabis

When someone close to you begins treatment with medical cannabis, it can bring both relief and uncertainty.

You may feel hopeful that their symptoms will improve. At the same time, questions about safety, legality and their long-term impact are common. Many caregivers simply want clarity about what this treatment involves and how best to help.

In the UK, medical cannabis is prescribed by specialist clinicians under a regulated framework. It is not informal use. It follows a medical assessment, documented diagnosis, and structured follow-up.

Understanding that context is the first step toward confident support.

What medical cannabis means in a UK clinical setting

Medical cannabis in the UK is available via specialist prescription for certain conditions when standard treatments have not provided adequate relief.

Before prescribing, clinicians review medical records and previous therapies. Eligibility is assessed carefully. Follow-up appointments are built into the process.

Products are manufactured under regulatory standards. Cannabinoid content is measured and labelled. Treatment decisions are documented.

For caregivers, this distinction matters. Your loved one is participating in a monitored medical pathway, not self-directing treatment without oversight.

Clarity reduces unnecessary anxiety.

Why someone may be prescribed medical cannabis

Medical cannabis is typically considered for symptom management.

Common causes include chronic pain, neurological spasticity, certain treatment-resistant conditions and severe nausea. The goal is often improved comfort and daily functioning rather than cure of underlying disease.

Understanding the objective of treatment helps shape expectations. Improvement may be gradual. It may focus on sleep quality or pain reduction rather than dramatic transformation.

Realistic expectations protect both patients and caregivers from frustration.

What to expect during the early stages

Initial prescribing is usually cautious.

Dosing often begins at a low level and may increase gradually depending on response. This adjustment period can last several weeks.

During this period, you may notice changes in sleep, appetite, pain perception, or mood. Some individuals experience mild side effects, such as fatigue, dizziness, or dry mouth. Others notice minimal disruption.

Patterns matter more than isolated moments. One tired day does not define treatment outcome.

Encouraging open conversation about how the person feels, without pressure, creates space for honest reporting.

How caregivers can offer practical support

Support does not require clinical expertise.

It may involve helping your loved one remember appointments, encouraging adherence to prescribed dosing schedules and creating an environment that supports rest and recovery.

Tracking symptoms can also be helpful. Keeping a simple record of pain levels, sleep duration, or changes in energy over time provides useful context for follow-up consultations.

Avoid adjusting dosage independently. Treatment decisions should remain clinician-led. Even well-intentioned changes can complicate assessment.

Consistency in routine often makes a greater difference than constant monitoring.

Recognising normal adjustment versus concern

It is helpful to distinguish between expected adaptation and signals that require review.

Normal early adjustments may include mild fatigue, a temporary appetite change, or a slight variation in mood as dosing is refined.

Concerning patterns may include significant behavioural change, persistent cognitive impairment, escalating use outside prescription guidance or worsening physical symptoms.

If concerns arise, the appropriate step is communication with the prescribing clinic rather than confrontation at home.

Calm observation supports safer outcomes.

Addressing common caregiver worries

Is medical cannabis legal?

Yes, it is legal when prescribed by a specialist in the UK and used as directed.

Will this lead to dependency?

Risk varies by individual and formulation. Prescribing clinicians assess history and monitor ongoing use. Structured oversight reduces uncontrolled escalation.

Will personality change?

The aim of medical dosing is to control symptoms while maintaining daily functioning. If personality appears markedly altered, clinical review is appropriate.

Can they drive?

Patients must follow UK driving laws and ensure they are not impaired. Responsibility remains with the individual, guided by medical advice.

Clear information reduces unnecessary fear.

Supporting emotional wellbeing

Chronic illness often affects confidence and identity.

If medical cannabis improves sleep or reduces pain, emotional stability may improve indirectly. Relief from constant discomfort can change daily mood patterns.

However, stigma surrounding cannabis may create anxiety. Some patients worry about judgement from family or colleagues.

Caregivers can reduce this stress by maintaining a calm and informed perspective. Avoid dismissive language. Avoid dramatic framing.

Normalising the treatment as one medical option among many helps restore balance.

Encouraging independence while remaining present

Support is not the same as control.

Adults receiving treatment benefit from autonomy. Ask how much involvement feels helpful. Respect privacy where appropriate.

Over-monitoring can feel intrusive. Under-involvement can feel isolating.

The right balance usually lies in steady availability rather than constant oversight.

Simple check-ins often matter more than intensive supervision.

When broader support may be needed

Medical cannabis is rarely the only component of care.

Your loved ones may still require physiotherapy, psychological support, or disease-specific treatment. Encourage continuation of the broader care plan.

If mental health symptoms intensify or new physical issues emerge, additional medical review may be required. Medical cannabis should not replace comprehensive care.

A holistic perspective strengthens outcomes.

Understanding your own position as a caregiver

Caregiving can be emotionally demanding.

You may feel responsibility for monitoring progress. You may also feel uncertainty about whether you are doing enough.

Remember that you are not responsible for treatment success or failure. Your role is supportive, not clinical.

Seeking reliable information and maintaining open communication is often sufficient.

Confidence grows with familiarity.

Final perspective

Supporting a loved one with medical cannabis in the UK involves informed awareness, realistic expectations, and steady communication.

The treatment operates within a regulated medical system. It is prescribed for defined reasons and reviewed over time.

Caregivers do not need detailed pharmacological knowledge. They need understanding, patience and consistency.

Calm observation, open dialogue, and respect for a patient’s independence often provide the strongest foundation for a positive treatment experience.

https://marucanna.co.uk/blog/caregiver-guide-medical-cannabis/

reddit.com
u/markoj22 — 10 hours ago

Topical Cannabis Products

Topical Cannabis Products

Topical cannabis products are a form of medicinal cannabis applied directly to the skin. As such, they differ from other formats insofar as they are applied directly to a specific area and are not absorbed into the bloodstream or digested. Topical cannabis comes in a wide variety of different forms and strengths, depending on the manufacturer's specifications. These products have been purported to be used across a variety of areas. 

What are topical cannabis products?

Cannabis topicals are medicinal products that contain cannabinoids and are applied directly to the skin. These products work by penetrating the skin’s surface layer, or epidermis, to allow the cannabinoids to bind with the body’s cannabinoid receptor. Cannabis topicals come in a vast range of cannabis lotions, gels, balms, creams, salves and oils. The broad range of choice, consistency and cannabinoid content are designed for a number of different use cases. 

How do topical cannabis products work?

Topical cannabis products work by interacting with the cannabis receptors in our endocannabinoid system. When you administer a topical gel, balm or cream to a certain area of your skin, the cannabinoids it contains may interact with elements of the endocannabinoid system via transfer from the main layer of the skin diffusing into further layers of the epidermis. 

How are topical cannabis products made?

Topical cannabis products are made by adding a form of cannabis extract to a variety of topical types, from lotions to salves, creams or gels. In general, cannabinoids will be the key ingredient of topical cannabis products on the market, however, the rest of its composition can vary widely. Cannabis will be an ingredient in every topical cannabis product on the market, but the rest of their make up will vary widely. Balms and salves will often involve beeswax, while cannabis oil for the skin might contain other essential oils, but the proportions will depend on the individual manufacturer. The most important thing to note is the type and amount of cannabinoid the topical contains.

The two main cannabinoids used in topicals are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Most  cannabis topicals contain CBD, rather than THC. Although both come from the cannabis plant, they act in different ways and have different effects. CBD, which can also be found in the hemp plant, is not psychoactive, so will not make you feel ‘high’, whereas THC is psychoactive. As a consequence, CBD is found in more topicals even though THC absorption via topical absorption is very low. 

Administration of topical cannabis products

As with all medicinal products, the instructions for administering topical cannabis products should be ready carefully. For a patient that is using a new topical cannabis product, their doctor should recommend applying the topical to a small patch of skin. This way, they can see if the product reacts negatively with their skin. Once it has been established that the medicine does not cause a reaction with the skin , the prescribed  amount can be applied. It’s important to note that topicals must only be applied externally and patients should be reminded never to ingest or eat topical cannabis products. 

Currently, patients in Australia can only access medical cannabis through a valid prescription. The Therapeutic Goods Administration (TGA) has only approved a few cannabis medicines, but many unregistered cannabis products are still prescribable with special approval from the TGA.

What types of topical cannabis products are there?

There are a range of different topical cannabis products available. They have their own unique formulas and cannabinoid profiles that affect their suitability to different situations. The most common types of topical cannabis products are cannabis creams, cannabis lotions, cannabis oils for skin, cannabis salves, cannabis gels and transdermal cannabis patches.

Creams

In general, creams are smooth, versatile and easy to apply. Often, manufacturers add essential oils like tea-tree oil, to enhance the potential benefits to the skin. Creams may be applied several times a day, as per a patient’s prescription, dependent on their condition. They can be effective for elderly patients, who are not comfortable swallowing medication, and can also be effective at targeting specific areas directly. 

Lotions

In general lotions have a lighter consistency and viscosity than creams. In the skincare industry, they are used for moisturisation, due to their faster absorption and greater hydrating qualities.  One of the advantages of using a lotion is that you can make repeated applications throughout the day. The lighter consistency is suitable for patients who dislike the feeling of heavier ointments, balms or creams on their skin. Lotions can be used on the entire body, including the face, but should never be used internally. 

Salves

Salves or balms offer a thicker, denser texture and consistency than lotions, creams or oils. Like creams, balms may also contain different ingredients to create their thicker texture. Common ingredients in salves are butters like shea or mango, oils like coconut or jojoba oil and other topicals that have potential skincare benefits, such as anti-inflammatory qualities. 

Gels

Gels tend to be more watery compared to other topicals,  meaning they may be  absorbed more quickly. They should also be applied slightly differently, with users rubbing them deeply into the skin, rather than slowly massaging them onto the surface. 

Transdermal patches

Transdermal patches penetrate deeper into the skin to reach the bloodstream. They are painless and non-invasive and can deliver a steady release into the bloodstream. The advantage of prescribing a transdermal patch is that it allows a patient to apply it for a predetermined period without needing to take further action. 

https://www.kind.com.au/post/topical-cannabis-products

reddit.com
u/markoj22 — 1 day ago

The First Authorized Medical Cannabis Cultivation in the Canary Islands

The Canary Islands have officially entered the medical marijuana with permission from the region's first certified cultivation site.

Developed by Nivaria Tech à Tenerife, the project received approval from the’Spanish Agency for Medicines and Medical Devices (AEMPS) and aims to position the archipelago as a future hub for the production of pharmaceutical-grade cannabis.

Located on the site of former farmland, the new facility combines cultivation, post-harvest processing, and pharmaceutical manufacturing within a single complex. According to the company, this integrated approach is designed to meet the standards of the EU GMP (Good Manufacturing Practices) while improving the efficiency and quality of the products.

The natural climate offers a competitive advantage

One of the project's main strengths lies in the islands' unique environmental conditions. According to Valeriano Rodríguez, plant manager at Nivaria Tech, the local climate allows cannabis plants to benefit from natural light cycles that are difficult to replicate elsewhere.

«Other manufacturers, both in Europe and the United States, work with artificial light, whereas we will develop our active ingredients using sunlight. We hope that the chemotypes already present in the plants will be able to fully express themselves under the influence of solar light stress, rather than under artificial lighting,» explains Mr. Rodríguez.

ADVERTISING

The combination of constant sunshine, trade winds, and minimal temperature fluctuations creates conditions that are particularly favorable for outdoor cultivation. These characteristics also enable the company to achieve a rapid production cycle, with six harvests per year thanks to crop rotations every 60 days.

Technology and Traceability at the Heart of the Project

Beyond culture, Nivaria Tech has focused on technology and pharmaceutical standards. The company has developed and patented its own plant traceability software, which tracks every stage of production—from cloning to cultivation, through harvesting, packaging, and laboratory testing.

The facility also incorporates advanced contamination control systems, including hydrogen peroxide generators and cryopasteurization technology designed to eliminate bacterial contamination through cold treatment. According to the company, only three machines of this type are currently in operation throughout Europe.

Security measures are just as rigorous. The site is under constant surveillance, with armed security personnel, reinforced infrastructure, and a dedicated bunker for storing pharmaceutical materials—all of which are necessary to comply with European pharmaceutical regulations.

«Our project not only makes us the first company in the Canary Islands to obtain this application and authorization, but also positions us as a company committed to expertise, the circular economy, and the use of renewable energy for power generation (…) »We aim to produce a medication that provides the end user with an experience—not only in its use, but also in its traceability,” he explained.

A Broader Vision for the Canary Islands

The company believes it could help build a broader ecosystem pharmaceutical manufacturing in a region that currently imports medicines but has limited local production capacity. Mr. Rodríguez argues that clearer regulations and stronger institutional support could encourage other pharmaceutical manufacturers to set up operations in the archipelago.

«At the Ministry of Health level, as well as at the national level, a synergy could be created that would allow the Canary Islands to have an AEMPS delegation and an inspection service for manufacturers. »Right now, many manufacturers of active pharmaceutical ingredients are backing out because nothing is in place yet, and they don’t want to be the first to set this up. We’ve set a precedent, not only in the field of cannabis but also for all pharmaceutical products,” he argues.

https://www.newsweed.fr/en/first-medical-cannabis-cultivation-in-the-canary-islands/

u/markoj22 — 2 days ago

VEAZY: an overview of Storz & Bickel's most compact vaporizer

Advertisement. This article was created in cooperation with Storz & Bickel .

The best vaporizer for beginners is one that feels simple to use without compromising on quality. That's exactly what the VEAZY is built for: the premium Storz & Bickel experience, now available in a true pocket-sized format.

Some things don't have to be complicated to feel high-quality. Those considering a vaporizer for the first time usually want exactly that: proven quality, intuitive operation, and consistent results every time. The VEAZY is the latest innovation from Storz & Bickel, built on the foundation of over 25 years of experience from the brand that once helped define the category with the legendary VOLCANO. What's new is how accessible this expertise now is: simply fill, press a button, and enjoy.

Plug it in and get going: the VEAZY is made for uncomplicated everyday life. Photo: Storz & Bickel

>

Premium can be this simple

Behind the simple operation lies true engineering ingenuity. At its core is a patented combination of convection and conduction heating: Hot air flows through the herb material, heating it simultaneously via the ceramic-coated filling chamber. The result is a dense, flavorful vapor that can be enjoyed in just 40 seconds. No settings, no studying, no mistakes required: A single button brings the VEAZY up to temperature, and for those who want even more, there are boosters and superboosters. No compromise on quality, just without the hassle.

One button, clear display, flip-up mouthpiece: the VEAZY in Dynamic Blue. Photo: Storz & Bickel

For everyone who is starting now

The VEAZY is the most compact vaporizer Storz & Bickel has ever built: lightweight, powerful, and truly pocket-sized. It's there when you need it and then discreetly disappears into your jacket. Four colors—Alluring Black, Inspiring Orange, Dynamic Blue, and Charming Pink—make it a device that complements your personal style, rather than just being a piece of technology. This makes it the ideal companion for beginners: a premium experience that feels like you've always used it and opens the door to your own personal ritual.

💬 Hemp Buddy — your cannabis expert

🌿 Questions about this topic? Just write and ask — I'll help you!

Send

Profile: Storz & Bickel VEAZY

  • Type: Portable vaporizer for dried herbs, Made in Germany
  • Heating system: patented combination of convection and conduction
  • Heating time: approx. 40 seconds to 180 °C
  • Temperature range: 40–210 °C · Base 180 °C + Booster + Superbooster (90 s each)
  • Airflow: ~10 l/min, low draft resistance
  • Filling chamber: ceramic-coated, 1.4 cm³
  • Material: medical-grade PEEK, UL-8139 certified
  • Battery & Charging: Lithium-ion, USB-C, LED charging indicator
  • App: S&B Web App via Bluetooth (temperature, firmware, device information)
  • Dimensions & Weight: 3.7 × 13.4 × 3.5 cm · 134 g
  • Colors: Alluring Black, Inspiring Orange, Dynamic Blue, Charming Pink
  • Product page: VEAZY at Storz & Bickel

https://www.hanf-magazin.com/genusskonsum-von-cannabis/cannabis-vaporisieren/storz-bickel-veazy-vaporizer/

reddit.com
u/markoj22 — 2 days ago

Are THC vapes a good choice for chronic pain?

If you’re living with chronic pain, chances are you’ve already tried a few conventional treatment options. Pills, patches, stretches, distractions. Maybe they helped. Maybe they didn’t. For some, the search for relief is a never ending stuggle.

That’s where THC vapes are starting to play a role here in the UK. These medical cannabis devices offer fast-acting effects without the fog that often comes with traditional pain meds. Some people use them for flare-ups. Others build them into a daily routine.

In this article, we’ll look at why more UK patients are turning to medical cannabis treatment for chronic pain, how THC vapes actually work in the body, and what to think about if you’re considering one for long-term pain. No fluff. No sales pitch (we don’t even sell them).

Just practical info to help you decide what’s right for you.

Key takeaways

  • THC vapes are legal in the UK with a private medical cannabis prescription
  • Vaporising offers faster onset than oral options and allows for flexible, in-the-moment dosing
  • Dry herb and oil cartridges each suit different routines and symptom patterns
  • THC affects how pain is perceived, helping shift the body’s response rather than blocking it
  • A simple eligibility check is the first step to accessing a legal prescription for THC vapes in the UK

Why more people with chronic pain are turning to THC vapes UK

Chronic pain is a stubborn companion for millions across the UK. It lingers beyond injuries, resists prescriptions, and quietly chips away at everyday life. For many, standard treatments like opioids or anti-inflammatories either don’t work well or bring problems of their own. Side effects build, tolerance creeps in, and the original issue remains.

More people are now turning to medical cannabis.

Legal via private prescription, it offers an alternative for those who’ve run out of road. Among the formats available, THC vapes have become especially popular. They work quickly, they’re easy to use, and they offer a sense of control that pills often take away.

What makes chronic pain so difficult to treat?

There isn’t always a visible cause. Chronic pain can flare up long after an injury has healed, or settle in without warning. It can affect nerves, muscles, or joints, or move around with no clear pattern.

Most patients try more than one treatment. Many get stuck between medications that take the edge off and those that knock them sideways. What helps one person may not touch another.

The process is slow, and rarely simple.

Why are UK patients looking beyond painkillers?

There’s only so much patience you can have with side effects that outweigh the benefits. People are tired of being foggy, tired of waiting, tired of feeling like they have no options.

THC-based pain relief offers something different. Vaping gives fast results and a smoother experience. It fits into a routine, rather than dictating one. That matters when pain is part of your everyday experience.

What happens in your body when you vape THC?

THC doesn’t block pain directly. What it does is interact with endocannabinoid receptors in the body, particularly CB1 receptors, which are found throughout the brain and spinal cord. These receptors help shape how we process discomfort. The result isn’t an on-off switch, but a shift in how pain is felt and responded to.

When you inhale from a vape, THC enters the lungs and reaches the bloodstream quickly. Most people feel the effects within five minutes or so. That speed can be important during a flare-up, when something slower simply wouldn’t cut it.

Vaping also allows for small, deliberate doses. One puff might take the edge off. Two might bring fuller relief. Because the effects arrive quickly and predictably, patients often find it easier to match their intake to how they’re feeling in the moment. Over time, this kind of dosing becomes intuitive. You learn what your body needs, and when.

And since the THC isn’t passing through the stomach or liver, the experience tends to be more consistent. No long waits. Fewer surprises. Just a bit more control over something that rarely offers much.

Why is fast onset important for chronic pain?

Chronic pain can shift throughout the day. Some people wake up with it, while others feel it building over time. A vape offers a way to respond quickly, without having to wait for oral treatments to take effect.

The portability and ease of use also suit daily routines. A pocket-sized vape is simple to carry, needs no preparation, and can be used without fuss. For people managing long-term pain, that convenience often becomes a vital part of staying well.

Weed vaporizers vs THC vape pens: What’s better for chronic pain?

Both dry herb vaporisers and THC vape pens are widely prescribed in the UK. Each offers unique benefits for people managing chronic pain. The best choice depends on your symptoms, lifestyle, and how you prefer to medicate.

Dry herb devices give patients access to full flower with minimal processing. Oil pens offer a more discreet and user-friendly experience, with many now using full-spectrum or live extract formulations that preserve much of the plant’s original profile.

Why some patients prefer dry herb vaporizers

Dry herb vaporisers allow you to vape whole cannabis flower. This means you can benefit from the full cannabinoid and terpene profile of the plant, which may help with complex pain conditions. It also gives you the freedom to try different strains and adjust based on how you feel that day.

A strain that works in the morning might not suit the evening. Being able to switch cultivars lets you personalise treatment over time.

Why others choose THC vapes UK

THC oil vape pens are chosen for their convenience. Most cartridges prescribed in UK clinics today contain full-spectrum or live extracts, not just pure THC isolate. This means patients can still access a broad cannabinoid profile, just in a more portable format.

You don’t need to grind, clean, or charge a bulky device. You attach a cartridge, inhale, and feel the effects in minutes. That speed matters when pain flares up during work, travel, or social situations.

Pens are discreet, easy to carry, and low in odour. For people who need relief without interruption, they offer a practical solution. Many patients vape their prescribed flower at home and oil vapes during the day or while they are out and about.

How to access THC vapes legally in the UK for chronic pain

If you’re living with chronic pain and nothing seems to take the weight off, medical cannabis may be worth considering. While you won’t find THC vapes on the NHS or behind the pharmacy counter, they are legal with a private prescription from a specialist clinic.

The process is relatively simple. A doctor reviews your symptoms and medical history to see whether cannabis might offer some relief. If they believe it’s appropriate, you’ll receive a prescription for products like THC vape cartridges, which can then be delivered straight to your door.

What’s the process for getting a prescription?

Most clinics follow the same basic steps. You start with an eligibility check, usually done online. If you qualify, you’ll be booked in for a consultation with a doctor who understands your condition. From there, if cannabis is prescribed, you’ll be given access to follow-up care, repeat scripts, and patient support throughout your treatment.

What formats and options are available now?

Medical cannabis in the UK now comes in a range of formats:

  • Dry herb for use with flower vaporisers
  • THC oil cartridges for discreet, fast-acting relief
  • Medical cannabis oil options for sublingual application

Final thoughts: Are THC vapes right for your chronic pain?

Maybe, maybe not. But at least all UK residents now have the legal right to find out for themselves, without having to worry about being on the wrong side of the law.

Vapes, in particular, have become a favourite for patients suffering through chronic pain issues. They work quickly, offer a level of control you don’t get with capsules or oils, and are easy enough to use in the middle of a difficult day. For symptoms that come and go without warning, that kind of responsiveness can be helpful.

Some people prefer flower. Others like the simplicity of a cartridge. The point is not which one is best, but which one makes sense for you. What fits your routine, your body, your rhythm, and your symptoms.

https://medicalcannabis.co.uk/are-thc-vapes-a-good-choice-for-chronic-pain/

u/markoj22 — 2 days ago

Mounjaro made me five stone lighter AND shed the awful hormone condition that's destroyed my life...but now I'm done with the jab

At their worst, Natalie Lavergne's intense food cravings could see her easily consume 1,400 calories-worth of praline chocolates in a single sitting. 

The 42-year-old, from Horsham, spent decades battling a sweet tooth compounded by living with the incurable condition polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

Ms Lavergne is one of around four million women in the UK with the condition.

Among its many symptoms, PMOS can reduce fertility, trigger intense weight gain, and increase the risk of diabetes and heart disease.

Slimming World, Weight Watchers, SlimFast shakes and painstaking calorie counting all brought temporary success to the director of a relocation company, who at her heaviest weighed 14st 3lb.

Then, last June, after her daughter's school raised concerns about the five-year-old's health, Ms Lavergne made a drastic decision in order to be a better example for her daughter.

Like at least 2.5 million other people in the UK, Ms Lavergne decided to take weight-loss drugs, following a recommendation from her sister-in-law.

Just over a year later, Ms Lavergne is an astonishing five-and-a-half stone down.

Natalie Lavergne's food habits could see her easily consume 1,400 calories-worth of praline chocolates in a single sitting

Ms Lavergne used Mounjaro for a year and shed a whopping five stone, but now she's ready to quit the jabs

Speaking to the Daily Mail about her decision to use the jabs she said: 'I thought, I need to make sure that I'm finding the best solution for me and set the right example. 

'And that's not eating a box of Guylian [praline chocolate seashell treats] on a random Tuesday night'.    

With the help of the drug, she now weighs a slight 8st 12lb - a loss of around 75lb - and says her life and confidence have both been completely transformed.

'I'm in my 40s, but I feel like a teenager again. But I have a little bit more wisdom than I had in my 20s, so I kind of know what's important and what to enjoy now.'

Not only does she feel younger, but she also credits the powerful jab with banishing many of the PMOS symptoms that have plagued her life since her 20s.

These included irregular periods – she would sometimes go an entire year without a bleed.

Her blood sugar levels were also high due to the resistance she'd developed to the hormone insulin, which converts sugar from food into energy.

Insulin resistance is a common complication of PMOS, as is joint pain which Ms Lavergne regularly battled.

But she says Mounjaro successfully got rid of these symptoms, as well as her food cravings – meaning no more chocolate indulgences. 

Yet, she initially stopped injecting the drug in November once she reached her goal weight.

But when some of her PMOS symptoms began to return - along with the 'food noise' that had previously encouraged her unhealthy eating habits - she restarted the drug four months later. 

From next month, however, she plans to switch to the newly approved Wegovy pill instead.

Health officials greenlit the drug - a tablet version of the highly effective once-weekly Wegovy injection - for private use last month, although it is not clear when it will be available on the NHS.

Ms Lavergne has dropped five-and-a-half stone since using Mounjaro and says her life has been transformed - yet she will still ditch it for the Wegovy Pill

After stopping the medication for eight months she started to notice changes

Private waiting lists are believed to have soared close to 100,000 as Britons scramble to secure the game-changing GLP-1 treatment, which can help people with obesity lose up to 17 per cent of their body weight after 64 weeks, compared to around 22.5 per cent on Mounjaro.

Ms Lavergne is one of many who is fed up of the weekly injections, even though she's suffered barely any side effects. 

'You are injecting on a weekly basis, and it's not ideal, in my opinion,' she said.

'If I'm going to do this long-term, do I really want to be injecting every week when I can just take a daily pill? No. That's my mentality around it.

'I'm not trying to lose more weight, I'm where I want to be. So this is now the perfect time because I think, I can try it, and if it doesn't work well, I can always go back to Mounjaro.'

Going without weight loss medication had a significant impact on Ms Lavergne's health.    

'Although I didn't regain a huge amount of weight, I did start feeling like all of a sudden things were starting to change,' she says.

She noticed a return of some of her PMOS symptoms such as unstable blood sugar, and started to crave high calorie foods again. 

In March, University of Cambridge scientists found that stopping weight loss jabs can leave patients heavier than they were before they began the treatment. 

Researchers say around half the weight lost during treatment is usually muscle and if the regained mass is mainly fat, patients' long-term health may be better if they had not taken the drugs at all.

In January, experts concluded that the likes of Wegovy, Mounjaro and Ozempic would benefit patients most if they remained on them for life.

Professor Susan Jebb, adviser to ministers and the NHS on obesity, said: 'Obesity is a chronic relapsing condition, and I think one would expect that these treatments need to be continued for life, just in the same way as blood pressure medication.'

https://www.dailymail.com/health/article-15981675/mounjaro-hormone-condition-weight-loss-jabs.html

u/markoj22 — 2 days ago

What Makes Medical Cannabis Different from Recreational Cannabis?

Cannabis is often spoken about as a single substance, yet the reality is more complex. Medical cannabis and recreational cannabis are not interchangeable, and in the UK they exist in completely different legal and clinical frameworks. For patients exploring treatment options through a clinic such as Marucanna, understanding these differences is essential before making any decisions.

Legal status in the UK

The most important distinction sits in UK law.

Medical cannabis is a prescribed treatment. It is only available through a specialist doctor following a clinical assessment. It is regulated under strict medical guidelines and supplied through licensed pharmacies.

Recreational cannabis remains illegal in the UK. Possession, cultivation, or supply outside a prescription context can result in criminal penalties.

This legal separation ensures that medical cannabis is treated as a controlled medicine rather than a lifestyle product.

Purpose of use

Medical cannabis is prescribed with a clear clinical goal. It is used to support specific diagnosed conditions where conventional treatments have not been effective or suitable. These may include chronic pain, multiple sclerosis-related symptoms, chemotherapy-related nausea, or certain anxiety disorders.

Recreational cannabis is used for non-medical purposes, typically for its psychoactive effects or relaxation. It is not designed, tested, or regulated for therapeutic outcomes.

The intention behind use changes how the product is formulated, prescribed, and monitored.

Composition and formulation

One of the key differences lies in cannabinoid content.

Medical cannabis products are carefully standardised. They are formulated with controlled ratios of THC (tetrahydrocannabinol) and CBD (cannabidiol), depending on the condition being treated. Each product batch must meet strict pharmaceutical quality standards, ensuring consistency in dosing.

Recreational cannabis varies widely in strength and composition. THC levels can fluctuate significantly, and there is no standardisation of CBD content or other cannabinoids. This lack of consistency makes it unsuitable for predictable medical use.

Prescribing and clinical oversight

Medical cannabis is only accessed through a prescription from a specialist doctor. At a clinic such as Marucanna, patients undergo a full medical assessment to determine suitability. If prescribed, treatment is monitored and adjusted over time based on response and side effects.

Recreational cannabis has no medical oversight. There is no prescribing doctor, no dosing guidance, and no structured follow-up.

Clinical supervision is a core part of medical cannabis treatment, ensuring safety and appropriate use over time.

Quality control and safety standards

Medical cannabis is produced under pharmaceutical-grade conditions. This includes testing for contaminants such as pesticides, heavy metals, and microbial impurities. The aim is to ensure that every dose is safe, consistent, and traceable.

Recreational cannabis does not follow these standards. The source, growing conditions, and processing methods are often unknown. This introduces variability in strength and potential exposure to harmful substances.

For patients with underlying health conditions, this difference in quality control is significant.

Dosing and administration

Medical cannabis is prescribed with specific dosing instructions. Patients are guided on how much to take, how often, and in what format (such as oil or flower for vaporisation). Adjustments are made based on clinical response.

Recreational use is self-directed, with no medical guidance. Dosing is inconsistent and often based on trial rather than clinical evidence, which increases the risk of unwanted effects.

Controlled dosing is one of the main reasons medical cannabis can be integrated into treatment plans safely.

Access pathways in the UK

Access to medical cannabis in the UK is restricted. Patients must be referred or assessed by a specialist clinic if they meet eligibility criteria. It is typically considered when standard treatments have failed or are not suitable.

Recreational cannabis has no legal access route. Any non-medical supply or use remains outside UK law.

Clinics such as Marucanna operate within this regulated framework to ensure patients receive appropriate care under medical supervision.

Why the distinction matters

Confusing medical and recreational cannabis can lead to misunderstanding about safety, effectiveness, and legality. Medical cannabis is not a general wellness product. It is a prescribed treatment used within a structured clinical system.

For patients considering this option, the key difference is control. Medical cannabis is guided by evidence, dosing, and on-going supervision. Recreational cannabis is not.

https://marucanna.co.uk/blog/medical-vs-recreational-cannabis/

reddit.com
u/markoj22 — 2 days ago

THC vapes in the UK: Why more UK medical cannabis patients are switching to THC vapes

THC vapes, cannabis dry herb vaporisers, and weed pens are now among the most popular ways to take prescribed medical cannabis in the UK. As more patients access legal treatment through private clinics, there’s growing interest in formats that feel practical, familiar, and easy to manage.

Vaporising cannabinoids is usually pretty easy and efficient, allowing patients to manage symptoms with more control and less disruption. For those prescribed medical cannabis flower, it also provides a lawful route of administration, since smoking cannabis (even when legally prescribed) will land you in trouble in the UK.

But there is a little more to it than pure legality. THC vapes are on the rise, not just here in the UK, but in all places where recreational weed and/or medical cannabis is legal. This begs the questions…

  • Why are so many people moving toward cannabis vaporisers?
  • How do dry herb devices compare to THC oil pens?
  • Is it all convenience, or does it make a difference for symptom relief?
  • What can patients expect when starting a medical cannabis vape prescription?

Key Takeaways

  • THC vapes offer fast, discreet symptom relief
  • Both THC vape and flower formats are legal with a prescription
  • Patients often combine both for flexibility and ease
  • UK clinics now offer more vape options than ever

Vaping offers patients better control, comfort and legal access

Medical cannabis flower is the backbone of the UK’s prescription market. It offers fast-acting relief, a wide range of cannabinoid profiles, and a flexible way to manage symptoms. But while doctors can prescribe cannabis flower, it’s illegal for patients to smoke it.

This makes perfect sense when you stop and think for just a second.

Inhaling smoke of any kind isn’t great for your health, and when you’re using cannabis for medical reasons, adding combustion into the mix starts to feel like the wrong tool for the job. Vaporisers heat the flower without burning it, releasing the active compounds in a clean stream of vapour rather than smoke.

It’s faster than oral oils or capsules, and far easier to manage when symptoms come and go throughout the day. There’s no rolling, no ash, and very little smell. The result is a more comfortable experience that still works quickly and can be adjusted in real time.

Why are weed vapes so popular among UK patients now?

Cannabis vapes, both dry herb and THC extract pens, just make life easy. When it comes to the trusty dry herb vaporisers, they come in two main types: portable and desktop. Portable devices fit neatly into a pocket or bag, while desktop models tend to live on a shelf and are used at home. Both work by gently heating cannabis flower to release active compounds as vapour, without burning the plant.

For THC oil pens, the process is even simpler. You attach a cartridge, press a button, and inhale. No grinding, no setup, no mess. This convenience matters, especially for people managing symptoms during the day or in shared environments. Vapour is lighter on the lungs than smoke and much lower in odour.

Patients often say vaporising helps them feel more in control of both their symptoms and their daily rhythm.

Let’s break down the options available to UK medical cannabis patients in 2025.

Dry herb vaporisers UK are growing in popularity (for good reason)

For many patients in the UK, dry herb vaporisers offer a familiar, plant-first approach to cannabis treatment. Whole flower is often seen as the most “natural” option, with minimal processing and a broad profile of active compounds. When vaporised correctly, it preserves more cannabinoids and terpenes than oil formats, which means patients can benefit from the full spectrum of the plant.

There’s also more choice. Different strains offer different effects, and dry herb allows patients to switch between them based on how they feel or what they need that day. Devices have come a long way, too. Once large and clinical-looking, they’re now smaller, quieter, and more user-friendly.

What are the key benefits of dry herb vaporisers?

Dry herb vaporisers deliver more than just THC. Patients get the full profile of the plant, including CBD, minor cannabinoids, and the terpenes. This helps some people fine-tune treatment for things like anxiety, sleep or pain.

You can also choose strains with specific effects. There are uplifting options for day use, and more calming options at night. Vapour is smoother than smoke, and with flower prescriptions, dry herb devices can be more cost-effective over time.

Are there downsides to dry herb devices?

They do require a bit more effort.

You’ll first need to grind the flower, clean the chamber, and learn how temperature affects vapour. They also tend to smell more than oil pens and cost more upfront.

Which brings us to the almighty rise of the THC vape!

THC vape pens: A cleaner, simpler way to medicate

THC vapes, weed oil vapes, “penjamins”. Whatever you call them, they’ve become one of the most popular ways to take medical cannabis in the UK. Easy to carry, quick to use, and low on effort, these pocket-sized pens are ideal for anyone who wants fast relief without the faff.

They work with pre-filled cartridges, usually using a standard 510-thread battery. You screw it in, inhale, and that’s it. There’s no grinding, no rolling, no smell to explain. The vapour is smooth, and the effects tend to come on within a few minutes - helpful if you’re managing things like anxiety, nausea or chronic pain during the day.

How do THC vape pens work in practice?

They’re simple by design. The pen gently heats the oil until it produces vapour. Most are draw-activated or button-controlled, and many are fully rechargeable. You get consistent dosing, minimal maintenance, and a device that fits in the palm of your hand.

They’re also discreet. No visible smoke, no strong smell, and no one giving you sideways looks at the park.

What are the pros and cons of THC vapes UK over dry herb weed vapes UK?

Pros

  • Convenient, portable, ready to go
  • Fast onset and clear dosing
  • Good option for first-time patients

Cons

  • Fewer strain choices than flower (right now, but that will change in the coming months/years)

Should you choose dry herb or oil? Here’s how to decide

Both dry herb and THC oil vapes are legal in the UK with a prescription, and both are widely used by patients. While it’s often assumed that oil pens contain isolated THC, many actually use full-plant extracts or live resin. These formulations preserve a broad range of cannabinoids and terpenes, offering similar benefits to whole flower.

The key difference lies in the format. Dry herb vaporisers give you access to strain-specific effects and a more hands-on approach. You can adjust temperature, rotate cultivars, and tailor the experience to different times of day or symptom patterns.

THC oil vapes are chosen for their simplicity. You attach a cartridge, inhale, and feel the effects within minutes. They’re discreet, consistent, and easy to use at work or while travelling. Many patients prefer oil during the day and flower at home.

What’s the best option for your routine and symptoms?

There’s no single answer. Dry herb suits patients who want flexibility and plant variety. Oil vapes work better for those who prioritise speed, ease and discretion. Both are great in different ways. It can also depend on the condition you are treating with medical cannabis.

As the UK market evolves, more clinics are offering a wider range of UK THC vape options. That means patients can expect better choices and more control over how they medicate. Over time, most will likely use a mix of both formats, depending on their needs.

https://medicalcannabis.co.uk/thc-vapes-in-the-uk-why-more-uk-medical-cannabis-patients-are-switching-to-thc-vapes/

reddit.com
u/markoj22 — 2 days ago

Germany Ends Public Health Insurance Coverage for Medical Cannabis Flowers

The German Bundestag has enacted new legislation eliminating reimbursement for medical cannabis flowers as part of the country's mandatory health insurance system (GKV). This measure is part of the broader framework of the GKV Premium Rate Stabilization Act, a law aimed at reducing spending in Germany's public health care system.

ADVERTISING

Under the new rules, as announced by, among others, Business of Cannabis, patients covered by the GKV, which accounts for approximately 90% of the German population, will no longer be eligible for reimbursement for prescribed cannabis flowers. The reform also introduces stricter conditions for reimbursement of cannabis extracts, requiring patients to undergo a mandatory six-month course of treatment with an approved cannabis-based medication before the extracts can be covered in most cases.

These changes have drawn sharp criticism from healthcare professionals and professional associations, who argue that the reform risks limiting access to treatment for seriously ill patients, while doing little to reduce healthcare costs.

Cannabis flowers are no longer reimbursed

The reform amends Section 31(6) of Book V of the German Social Code, which defines which cannabis-based medications are eligible for reimbursement.

Previously, patients with serious illnesses could receive a Reimbursement for cannabis flowers, the cannabis extracts, as well as for cannabinoid-based medications such as dronabinol and nabilone, provided that certain medical conditions are met.

ADVERTISING

Under the new legislation, flowers have been completely removed from the list of reimbursable treatments. No transition period has been provided for patients already undergoing treatment, which means that those who currently rely on reimbursed flowers risk losing their coverage as soon as the law takes effect.

According to Dr. Christiane Neubaur, executive director of the Verband der Cannabis versorgenden Apotheken (VCA):

«Many patients who currently receive prescription cannabis-based medications do not meet the criteria for these approved indications. A six-month general priority review period for ready-to-use medications can therefore create significant barriers to access if there is no duly authorized ready-to-use medication for the specific indication,» she wrote on LinkedIn.

For many doctors, the lack of provisions to preserve acquired rights creates uncertainty for patients whose treatment is already stable.

ADVERTISING

New six-month requirement for cannabis extracts

Although the cannabis extracts While they remain eligible for reimbursement, access to them has become significantly more restrictive. Patients must now first undergo a six-month therapeutic trial with a ready-made cannabis-based medication before reimbursement for custom-prepared extracts can be granted, except in limited situations where exemptions apply.

Currently, only three approved cannabis-based medications meet this requirement:

  • Sativex for spasticity associated with multiple sclerosis.
  • Epidyolex for certain severe forms of epilepsy.
  • Canemes for chemotherapy-induced nausea and vomiting.

L’Exilby, approved in June 2026 for chronic back pain, is not currently available to patients pending pricing.

One of the practical challenges highlighted by critics is that many patients receiving medical marijuana are being treated for conditions that fall outside the approved indications for these drugs. Prescribing them would therefore often require off-label use, accompanied by additional clinical justification and separate authorization from public insurers.

The industry is questioning the rationale behind cost-cutting measures

The German government has presented this reform as a cost-cutting measure for the mandatory health insurance system. Several organizations representing the medical marijuana nevertheless maintain that the economic reasoning is flawed.

According to Michael Greif, executive director of the Federal Association of the Cannabis Industry (BvCW), eliminating reimbursement for compounded medications could actually lead to an increase in spending, since approved finished drugs are often more expensive than those compounded in pharmacies.

The BvCW also highlights official prescription data, which show that approximately 76% of patients receiving reimbursement for cannabis are being treated primarily for chronic pain. Currently, only Exilby has an approved indication for this condition, but the product has not yet been the subject of the pricing negotiations required before systematic reimbursement can begin.

Antonia Menzel, president of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC), also questioned the government's calculations:

«This amendment doesn’t save a single euro; quite the contrary. It forces doctors to prescribe six-month supplies of medications that may end up costing more per month of treatment than the tried-and-true formula—and that aren’t even approved for most conditions. This has absolutely no place in a law intended to stabilize contribution rates.»

Industry representatives further argue that treatment decisions should continue to be based on individual clinical needs rather than on mandatory administrative procedures.

Limited impact expected across the entire German medical cannabis market

While the reform could have serious consequences for the patients affected, some analysts believe that its overall commercial impact will be relatively modest. According to Alfredo Pascual, head of strategy and business development at Cannamedical Pharma, the cost of flowers covered by social security amounted to approximately 125 million euros in 2025, which corresponds to about 7.5 metric tons per year.

By way of comparison, the Total German market for medical cannabis flowers now exceeds 20 metric tons per month, which means that reimbursed prescriptions account for only about 3 to 4% of the total volume of flowers.

Mr. Pascual argues that a significant proportion of patients who lose their entitlement to reimbursement are likely to continue their treatment by paying out of pocket, especially since the over-the-counter prices charged by pharmacies remain significantly lower than those on the black market. Over-the-counter telemedicine providers have already indicated that their services would not be affected by this legislative change.

He therefore believes that this reform is of great importance to individual patients, while having only a limited effect on the market as a whole. As Mr. Pascual wrote:

«A negative sign? Yes. A real challenge for certain individual patients, as well as for pharmacies that specialize in cannabis covered by statutory health insurance (GKV), where prices are significantly higher than those in the over-the-counter market. But a market shock? The data suggest not.»

What's next?

The legislation does not require the approval of the Bundesrat to take effect, although the German upper house could still refer the measure to a mediation committee, which could delay its implementation and reopen discussions on the provisions regarding cannabis.

The BvCW has already urged the German states to explore this option. Among its proposals are reducing or eliminating the requirement for a six-month treatment period, introducing broader exemption clauses for patients for whom approved medications are not suitable, and establishing transitional provisions for individuals already receiving reimbursed cannabis-based treatments.

The outcome of the reimbursement negotiations regarding Exilby will also be closely monitored. Until this medication is fully available through the reimbursement system, many patients suffering from chronic pain could face significant practical obstacles under the new regulatory framework.

https://www.newsweed.fr/en/germany-end-of-reimbursement-for-medical-cannabis-flowers/

u/markoj22 — 2 days ago
▲ 2 r/KeltoiWellness+1 crossposts

Exploring the Wellness Benefits of CBD Oil: A Natural Approach to Wellbeing

by CBD Leafline | CBD Benefits

Derived from the hemp plant, CBD oil is gaining popularity as a natural remedy for a wide range of issues. Let’s explore some of the benefits of CBD oil that are making it a staple in many people’s wellness routines.

1. Promotes Relaxation and Stress Relief
One of the most popular uses of CBD oil is for relaxation and stress relief. Many users report feeling a sense of calm and relaxation after taking CBD oil, making it an ideal option for those looking to unwind after a long day or manage everyday stressors.

2. Supports Sleep Quality
Poor sleep can have a significant impact on overall wellbeing. CBD oil may help promote better sleep by calming the mind and body, making it easier to fall asleep and stay asleep throughout the night. Many individuals find that incorporating CBD oil into their bedtime routine leads to improved sleep quality and a more refreshed feeling upon waking.

3. Eases Discomfort and Supports Recovery
Whether it’s occasional discomfort from exercise or chronic discomfort from underlying health conditions, CBD oil may offer relief. Some users report experiencing reduced discomfort and faster recovery times after incorporating CBD oil into their daily regimen. Its natural anti-inflammatory properties may help alleviate discomfort and promote a faster healing process.

4. Enhances Mood and Emotional Wellbeing
CBD oil is also praised for its potential to enhance mood and support emotional wellbeing. Many users report feeling more balanced and uplifted after taking CBD oil, making it a valuable tool for managing mood fluctuations and promoting a positive outlook on life.

5. Promotes Skin Health
CBD oil is not only beneficial when ingested but can also be applied topically to promote skin health. Its anti-inflammatory and antioxidant properties make it a popular ingredient in skincare products, helping to soothe irritation, reduce redness, and promote a clear, glowing complexion.

6. Supports Overall Wellness
Beyond its specific benefits, CBD oil is believed to support overall wellness by promoting homeostasis within the body. By interacting with the endocannabinoid system, CBD oil may help regulate various bodily functions, including mood, sleep, appetite, and immune response, contributing to a greater sense of balance and vitality.

In conclusion, CBD oil offers a myriad of wellness benefits that make it a valuable addition to any holistic health regimen.

From promoting relaxation and stress relief to supporting sleep quality, easing discomfort, enhancing mood, and promoting skin health, CBD oil offers a natural approach to achieving optimal wellbeing.

Whether you’re looking to unwind after a long day, manage discomfort, or simply support your overall health, CBD oil may be worth exploring as a gentle and effective wellness solution.

https://cbdleafline.co.uk/benefits-of-cbd-oil/

u/markoj22 — 3 days ago

Redefining the standards of UK cannabis

Dalgety Ltd has entered into a partnership with Curaleaf Laboratories aimed at supplying pharmaceutical-grade cannabis medicines within the UK medical cannabis market. The arrangement combines Dalgety's cultivation operations, which are certified to EU-GMP standards, with Curaleaf Laboratories' pharmaceutical manufacturing and distribution capabilities. According to the companies, this creates a UK-based supply pathway that does not rely on imported cannabis flower, since Dalgety cultivates its product domestically. Dalgety states that it was the first company in the UK to hold licenses covering the cultivation, manufacture, and supply of EU-GMP medical cannabis flower from a single domestic site.

The cultivation facility, described as spanning over 30,000 square feet, is indoors and uses hydroponic growing methods along with automated systems for lighting, irrigation, humidity, and temperature control. The company reports that it uses AI-assisted environmental monitoring, batch traceability from propagation through to the final product, and air filtration systems it compares to operating theatre standards. Post-harvest processing is said to follow EU-GMP protocols, including microbial and cannabinoid testing.

The stated goal of this approach is to reduce variation between harvests in terms of THC and CBD content, terpene profiles, and microbial safety. Dalgety says its cultivation is overseen by staff with backgrounds in horticulture and biochemistry, some of whom have worked on cannabis cultivation projects internationally.

Through the partnership with Curaleaf Laboratories, cannabis grown by Dalgety in the UK is processed and distributed via a UK-based pharmaceutical supply chain, rather than being imported from overseas. The companies suggest that this arrangement can shorten the time needed to bring products to market compared with importation, and may reduce the likelihood of supply interruptions. Because Dalgety and Curaleaf Laboratories are both involved across cultivation, manufacturing, and distribution, the companies say this gives them oversight of the product at each stage, and gives prescribing clinicians a clearer view of where and how the product was made.

Dalgety operates under EU-GMP standards and has been subject to regulatory review by the MHRA and the Home Office. Its operations reportedly include environmental monitoring, microbial testing, stability testing, controlled drying and curing procedures, and quality assurance processes, along with monitored and secured facilities.

The company describes its work as involving controlled-environment agriculture, hydroponic systems, environmental monitoring technology, and efforts to stabilize cannabis genetics and phenotypes for consistency across batches.

Dalgety has also opened its cultivation facility to healthcare professionals, clinicians, pharmacists, researchers, and other industry stakeholders for visits. The company frames this as a response to the fact that much of the cannabis historically supplied to UK patients has been grown overseas, which limited opportunities for UK clinicians to see the cultivation and quality-control processes directly. These visits are intended to give visitors insight into cultivation standards, EU-GMP compliance procedures, environmental control systems, testing processes, and the regulatory framework governing UK cannabis manufacturing.

Dalgety and Curaleaf Laboratories describe their partnership as aimed at expanding access to UK-grown medical cannabis, improving supply chain reliability, and supporting regulatory compliance within the sector, framing this within a broader context of increasing patient demand for cannabis-based treatments in the UK.

https://www.mmjdaily.com/article/9858989/redefining-the-standards-of-uk-cannabis/?utm_medium=email

u/markoj22 — 3 days ago

When a teenager makes the ‘stupid choice’, their brain is working exactly as designed

When an adult refuses to let an injustice pass – stands up to a bully, or asserts their rights – we call it principle. When a fifteen-year-old retaliates to an insult thrown in a school corridor, risking detention, we call it a failure to think ahead. It’s easy to ascribe this to a not-yet-developed teenage brain: a convenient shorthand for assuming they simply cannot weigh consequences properly.

But this misunderstands the teenage brain. It works in a way that has been shaped by evolution for a unique and uniquely challenging time of life.

Humans repay kindness with kindness, bristle when they are cheated, and want rule-breakers to be made to pay. Infants of eight months already prefer those who behave well towards others, and the willingness to punish someone who breaks a rule grows stronger as children get older. Getting your own back registers in the brain’s reward system as genuinely pleasurable.

This is the argument at the heart of my research in evolutionary criminology. Punishment is one of the mechanisms that allowed cooperation to evolve. A group where cheating goes unanswered is a group that eventually stops cooperating. The teenager who hits back in the corridor is running on an ancient programme.

Adolescence turns the volume on these impulses up, and there are good reasons for that.

Why fifteen is different

The brain’s reward system, and the ventral striatum in particular, becomes far more responsive during the teenage years, peaking in mid-adolescence. The prefrontal cortex, which allows a person to inhibit an impulse rather than act on it, continues to develop into the third decade of life.

Adolescence is when a young person has to step away from their family and find a footing among peers. A brain that feels rewards keenly, that explores, that cares enormously what other people think and that defends its standing is well suited to that job.

The presence of friends alone is enough to raise risk-taking and to activate reward circuitry in ways that do not happen when teenagers are alone. Sensitivity to peer judgment and exclusion runs higher in adolescence than at any other point in life.

The price of the sensible choice

Teenagers do weigh up what they are doing. The costs that weigh most heavily on them are social, and adults consistently underestimate how heavy they are. Walking away in front of an audience can cost a young person their standing, and standing is the thing they most need at that age.

How they are perceived by their peers is incredibly important to teenagers. Zamrznuti tonovi/Shutterstock

A brain this sensitive to its surroundings will take its shape from whatever those surroundings contain. Exposure to high-risk environments and offending peers accounts for a very large share of whether young people break rules at all.

This sensitivity is also why researchers increasingly describe adolescence as a window of opportunity. A calm environment that prioritises fair outcomes and in which people are treated with respect will shape how teenagers behave.

Knowledge into practice

If a young person trusts the system to deliver a just outcome, their brain’s urgent need for retribution is dialled down, allowing the prefrontal cortex to catch up. At school, this might mean an approach where a trained staff member mediates a conversation between conflicting students, ensuring both are heard and a mutually acceptable resolution is reached, rather than relying on punishment.

At home, it could be as simple as a parent consistently and calmly intervening in a sibling dispute to reach a fair outcome, rather than letting children “sort it out themselves” and risk the more powerful one imposing their will.

Teachers and parents can also try to create an environment where the rewarding thing to do and the sensible thing to do point in the same direction. For instance, a school could create a peer-to-peer tutoring program where helping a classmate is also recognised with privileges or public acknowledgement – making it the “sensible” choice for social standing.

At home, this could involve framing chores not as a burdensome duty, but as a contribution to the family team, with the reward being more family leisure time together. This aligns the immediate payoff with the long-term benefit.

Another important strategy is to leave young people a way to back down without losing face. In a school, a teacher witnessing a brewing conflict might privately offer both students a “cooling-off” pass to a designated safe space, framing it as a chance to deescalate rather than as a punishment for fighting.

At home, a parent might say, “I can see you’re really angry right now. I need you to choose how you want to handle this: we can talk it through now, or you can take 20 minutes to cool off and we’ll come back to it. Your call.” This allows the teenager to disengage from a confrontation without appearing weak in front of peers or siblings.

Adolescence takes its shape from whatever we surround it with, which makes it the most promising few years we have to positively shape a life. It’s a window of opportunity where the right support, fair systems and understanding environments can have a greater impact than at almost any other stage of development.

https://theconversation.com/when-a-teenager-makes-the-stupid-choice-their-brain-is-working-exactly-as-designed-287503

u/markoj22 — 3 days ago

Measuring What Matters: Why Outcomes Will Decide the Future of Cannabis Medicine

The UK medical cannabis sector has spent seven years arguing for access. The next argument will be settled on outcomes, and judging by the evidence available right now, the industry is not equipped to win it.

The Lancet Psychiatry‘s systematic review of cannabinoids, published on 16 March, concluded that the available randomised controlled trial evidence does not justify the routine prescribing of medical cannabis for mental health disorders. 

Following its publication, the industry has been the target of a relentless media campaign, calling for tighter regulation, increased prescription oversight, and an overarching rethink of the entire sector. 

According to recent figures from NHSBSA FOI data, the number of private prescriptions more than doubled from 283,000 in 2023 to around 659,000 in 2024. 

UK prescriptions have scaled far faster than the clinical evidence base could match. Clinics that focus on keeping meticulous, credible, longitudinal patient data stand at a significant advantage. 

Not only do they have a solid evidence base to defend their prescriptions against such scrutiny, but have the opportunity to build a wider, more substantial case for the benefits so many of their patients experience with treatment. 

The evidence the trials cannot reach

One of the key studies referenced in the Lancet study was the Wilson review, which screened 5,774 studies and included 54 randomised controlled trials covering 2,477 participants. 

It found no significant benefit for anxiety, PTSD, psychotic disorders, OCD, anorexia or opioid use disorder, and no eligible trials at all for depression. 

Evidence certainty was rated very low or low under the GRADE framework, as Business of Cannabis reported at the time of publication. The review does not conclude that cannabinoids don’t work, but that the controlled evidence base is too thin to support routine prescribing at scale, and that the conditions driving prescription growth are precisely those for which trial evidence is weakest.

Dr Anne Schlag of Drug Science, which operates the UK’s largest non-profit medical cannabis registry, has argued that the patients most likely to seek a prescription are typically multi-morbid, sometimes carrying up to ten concurrent diagnoses, and would be excluded from RCT cohorts. 

The registry, now following more than 4,500 patients for up to five years, finds significant symptom reduction at three months in those with comorbid depression and PTSD. 

Uncontrolled data cannot, on its own, establish whether a treatment works. The patients’ UK clinics treat patients outside the RCT base, and finding a solution to this dynamic is now the critical problem for the industry to solve.What 1,669 patients told one clinic

In November 2025, Releaf, a CQC-regulated medical cannabis clinic and one of the UK’s largest, surveyed its active patient base. 

Of 1,669 respondents, 672 reported being prescribed for anxiety, depression, PTSD or a combination of the three. Participation was voluntary and uncompensated.

Writing in Releaf’s own blog, Sam North said the survey returned ‘a very consistent signal across all three conditions’. 

Among the mental health cohort, 80% rated their treatment very or extremely effective and 94% reported at least moderate effectiveness. 

Meanwhile, fewer than 4% reported limited or no effect. Improved quality of life was reported by 98%, improved daily functioning by 87%, and improved capacity for work or study by just under 70%. PTSD respondents reported the strongest overall response.

Survey data of this kind cannot do what an RCT does, the respondent pool is self-selecting and paying privately. Outcomes are self-reported, and there is no control arm. 

Releaf’s findings sit broadly in line with two recent peer-reviewed cohorts. A two-year case series of 698 depression patients drawn from the UK Medical Cannabis Registry, published in the Journal of Affective Disorders, found significant reductions in depression severity at one, three, six, 12 and 24 months. 

A December 2025 prospective cohort also found that patients above clinical thresholds fell from 81% (anxiety) and 76% (depression) at baseline to below 50% within three months.

The data that the system cannot see

In October 2025, Business of Cannabis analysed NHSBSA records covering more than 132,000 prescription entries. The agency confirmed that private cannabis prescriptions are ‘manually recorded from often handwritten prescriptions’ with ‘no standardised naming convention’. Product match rates fell as low as 77.5% for 2022, meaning nearly one in four prescription records that year could not be reliably assigned to a specific medicine.

That same fractured dataset underpins the figures now driving mainstream coverage. The Times‘ April investigation, which claimed ten doctors issued more than half of all UK cannabis prescriptions since 2019, drew on a bespoke FOI response that has not been published in full. 

Business of Cannabis has requested this same data, and will report it publicly once it has been received. 

This data issue cuts both ways. Critics work from a dataset that cannot reliably account for what each clinic does, and operators defend themselves without the outcomes record that would settle the question.

Oliver’s Law, launched by Oliver Robinson’s family, calls for a central NHS registry recording every prescription issued, alongside routine CQC inspections and published prescribing data. 

Many in the industry have argued for the same architecture for years. The reform climate has made it close to inevitable. The question is whether the registry is designed collaboratively, with the operators that hold the patient relationships, or imposed by a regulator working without them.

The next test

The CQC and MHRA already have the powers required to implement these changes and establish a sector-wide requirement to capture and publish standardised outcome measures, using validated instruments, at agreed follow-up intervals. 

Such a mandate would supply the longitudinal evidence the trial pathway cannot generate at scale, give regulators a defensible mechanism for distinguishing well-run clinics from poorly run ones, and give the sector the response it currently lacks when challenged on safety, scale or efficacy.

Whether a top-down mandated change is pushed through by regulators first, or whether the industry itself pulls together to produce a coordinated industry standard, those who are already building this evidence base will have a seat at the table whenever change is made. 

https://businessofcannabis.com/measuring-what-matters-why-outcomes-will-decide-the-future-of-cannabis-medicine/

reddit.com
u/markoj22 — 3 days ago

Cannabis can help soothe some symptoms of autism, new study finds

  • Medical cannabis treatment was associated with significant improvements in quality of life, anxiety and sleep for autistic adults over an 18 month period, according to new research from Imperial College London.

A new study that aimed to assess how people living with autism spectrum disorder (ASD) could benefit from medical cannabis has discovered positive results, with improvements observed across multiple measures over an 18-month period.

Published in the journal Neuropsychopharmacology Reports, the research highlights how treatment with cannabis flowers, cannabis oils, or a combination of both was associated with meaningful and beneficial outcomes across multiple metrics.

Scientists from the Medical Cannabis Research Group at Imperial College, London, conducted the trial. The data was supplied by 130 patients who had been diagnosed with ASD, were already being treated with cannabis medicine, and who were registered on the UK Medical Cannabis Register (UKMCR).

Patients were assessed at the beginning of the study and at regular intervals over an 18-month period. The results showed that they experienced significant improvements in areas including quality of life, anxiety, and sleep.

ASD is a neurodevelopmental disorder that is marked by challenges in social communication and interaction, alongside restricted and repeated behaviours. Patients can experience different symptoms, including but not limited to social communication and interaction difficulties, oversensitivity, being fixated on specific subjects and repeated behaviour patterns.

There are currently no recognised pharmaceutical treatments for ASD, although people living with the condition are often prescribed drugs such as antidepressants and stimulants for co-occurring conditions including ADHD and depression.

The treatments available for ASD are usually focused on the individual patient’s needs and rely heavily on therapy-based interventions that include behavioural, speech and language, and occupational therapies.

It is estimated that around 0.6% of the global population lives with ASD, and with the recent advancements in diagnosis techniques, such as the use of AI to scan facial expressions, this figure is rising.

People living with ASD are highly likely to experience other conditions alongside autism. Between 50 – 83% of people with ASD are thought to have to learn to cope with symptoms that often exacerbate their condition, including anxiety, sleep disorders, and depression.

Researchers on the study were not looking at cannabis as a cure or treatment for ASD itself, but rather an alternative treatment for the co-morbid conditions which often accompany it. Currently, many patients are prescribed drugs such as SSRIs and antipsychotics, which can cause unwanted side effects and are often poorly tolerated.

“ASD treatment does not seek to change the core features of the condition, but rather treat associated distressed behaviours or psychiatric conditions. There is a paucity of high-quality evidence on the efficacy of these therapies in ASD. Conventional pharmaceutical treatments may include selective serotonin reuptake inhibitors and atypical antipsychotics, such as risperidone and aripiprazole, which have shown to reduce some dimensions of symptoms associated with ASD,” the authors said.

To test the efficacy of cannabis for the treatment of co-occurring ASD symptoms, researchers assessed 130 patients who were living with ASD and who were registered on the UKMCR.

Participants completed an initial assessment at the beginning of the study in which they supplied details about their tobacco and alcohol use, cannabis status (if they used, didn’t use, or used to use it), amount of grey-market cannabis used and details about their current cannabis prescription. They were also asked to complete patient-reported outcome measures (PROMs), which would evaluate their general anxiety level, sleep, and quality of life score, and asked to provide details on how their condition has changed (PGIC).

Across all recorded measures, patients’ scores were observed to increase from baseline all the way through to 18 months, apart from the PGIC score, which showed improvements from 1 month through to 18 months.

From the cohort, 25 participants reported adverse events (AEs), with most being classified as either mild or moderate. The most common adverse events were insomnia, dry mouth and lethargy.

Notably, the median daily THC dose increased nearly tenfold during the study period, from 20mg/day at baseline to 192.25mg/day at 18 months, suggesting dose escalation was required to maintain effects.

Researchers noted that cannabis medicine had a positive effect on the co-occurring symptoms experienced by participants in this study, but acknowledged the study’s limitations due to the lack of a control group.

“This case series explored the outcomes of autistic adults treated with CBMPs. The findings indicate that CBMPs were associated with improvements in anxiety, sleep quality, and health-related quality of life,” the authors said in their conclusion. “While a proportion (19.23%) of the cohort reported adverse events, the majority were mild or moderate. As an uncontrolled observational analysis, the study cannot establish causation; reported changes should be interpreted as temporal associations and not as evidence of a treatment effect.”

The findings add weight to those of other studies investigating how cannabis medicines can be used to assist those living with ASD, with results suggesting that it can be used for short-term relief and advising against long-term reliance on cannabis.

https://www.leafie.co.uk/news/cannabis-symptoms-autism-study/

u/markoj22 — 3 days ago

How Fast Can You Get a Medical Cannabis Prescription in the UK?

For many patients exploring medical cannabis, the first question is simple: how long does it actually take to get a prescription in the UK?

The honest answer is that timelines vary depending on medical history, eligibility, and how quickly required information is provided. At Marucanna, the process is designed to be efficient, structured, and clinically compliant so patients are assessed without unnecessary delay.

In most cases, patients can move from initial enquiry to prescription approval in a matter of days, provided medical records and eligibility criteria are in place.

Typical timeline for a medical cannabis prescription

Most private medical cannabis clinics in the UK follow a similar structured pathway. At Marucanna, the process is designed around four clear stages:

1. Eligibility check (same day)

The first step is confirming basic suitability. Patients provide details about:

  • Medical conditions and symptoms
  • Previous treatments tried
  • GP details and relevant medical records
  • Personal information required for clinical review

This stage is straightforward and helps determine if a full assessment is appropriate.

2. Clinical review (1–3 days)

Once eligibility information is submitted, the clinical team reviews your case.

At this point, doctors assess whether:

  • You have a diagnosed condition suitable for treatment
  • Standard treatments have been tried without success
  • Medical cannabis is clinically appropriate under UK prescribing rules

Only specialist doctors registered in the UK can prescribe medical cannabis, so this review is essential for compliance.

3. Consultation appointment (often within 3–7 days)

If suitable, you are booked in for a specialist consultation.

This appointment is where:

  • Symptoms are discussed in detail
  • Treatment options are reviewed
  • A personalised prescription plan is considered

Many patients are surprised at how direct this stage is. If eligibility is clear and medical history is complete, the consultation can lead quickly to approval.

4. Prescription and dispensing (24–72 hours after approval)

If the specialist approves treatment:

  • A prescription is issued
  • A specialist pharmacy processes the medication
  • Medication is delivered securely to your door

In most cases, delivery follows approval within a few working days, depending on stock and pharmacy processing times.

Fastest possible timeline

For patients with clear medical records and a well-documented history, the fastest realistic timeline is:

3 to 7 working days from enquiry to prescription approval

This depends on:

  • How quickly medical records are provided
  • Whether eligibility criteria are clearly met
  • Appointment availability with a specialist
  • Pharmacy stock availability

What can delay the process?

Not every application moves quickly. Common delays include:

1. Missing medical records

Without GP summaries or treatment history, clinical review takes longer.

2. Unclear treatment history

Doctors must confirm that standard treatments have already been tried.

3. Eligibility uncertainty

Some cases require further review before approval can be considered.

4. Pharmacy stock availability

Certain prescribed medications may need to be ordered in.

Who is most likely to be approved quickly?

Patients tend to progress faster when they have:

  • A diagnosed chronic condition
  • Evidence of two or more failed treatments
  • Clear GP or specialist records
  • Stable, documented medical history

These factors allow clinicians to make decisions without delay and reduce the need for additional checks.

NHS vs private access times

It is important to understand the difference between NHS and private access:

  • NHS prescribing is extremely limited and usually restricted to specific conditions
  • Private clinics like Marucanna can assess suitability more quickly
  • Private pathways are structured for faster consultation and prescribing decisions

This is why most UK patients accessing medical cannabis do so privately.

https://marucanna.co.uk/blog/marucanna-medical-cannabis-timeline/

reddit.com
u/markoj22 — 3 days ago

Man arrested in Co Tyrone after police uncover cannabis factory

A man has been arrested following the discovery of a cannabis factory in the Moy area.

The arrest came after a police search of a property in the Ardean Manor area on Friday, July 17.

Police said that approximately 300 cannabis plants were found.

A man in his 30s was arrested on suspicion of a number of offences including cultivation of cannabis possession of a class B controlled drug, possession of a class B controlled drug with intent to supply and being concerned in the supply of a class B controlled drug.

“He remains in police custody at this time,” the PSNI said.

“Targeting drugs supply is a priority for the Police Service of Northern Ireland.

“Our investigation into this discovery is ongoing, and I would ask any member of the public who has any information, which could be of assistance to police to contact the non-emergency number 101, quoting reference number 1261 18/07/26.

“Alternatively, information can also be provided to the independent charity Crimestoppers on 0800 555 111 which is 100% anonymous and gives people the power to speak up and stop crime.”

https://www.belfasttelegraph.co.uk/news/man-arrested-in-co-tyrone-after-police-uncover-cannabis-factory/a/158926571.html

reddit.com
u/markoj22 — 3 days ago

Cannabis Gummies Move Into the Multivitamin Aisle

As cannabis brands look for new ways to reach consumers, some are developing products that look less like recreational edibles and more like daily wellness supplements.

The latest example comes from MariMed Inc.’s Betty’s Eddies™, which has introduced Betty’s Bite-A-Mins, a daily wellness chew that combines cannabinoids with a multivitamin-inspired formula.

The tropical smoothie-flavored chews combine 30mg of CBD, full-spectrum cannabis, Vitamin C, Zinc, and a full daily serving of Vitamin D3 in a gummy format. The launch shows how cannabis brands are experimenting with new ways to position cannabinoids, moving gummies closer to the functional wellness and supplement categories.

Vitamin C and Zinc are often used for immune support, while Vitamin D3 is a common part of daily vitamin routines. Adding CBD and full-spectrum cannabis gives Betty’s Eddies a new twist on the gummy category and introduces a new opportunity for the industry.

“Consumers are increasingly looking for products that fit seamlessly into their daily routines,” said Sara Rosenfield, Brand Director for Betty’s Eddies. “With Betty’s Bite-A-Mins, we listened to that feedback and created a core product that delivers a higher dose of CBD alongside vitamins many people already take every day.”

The product follows what is happening across food and beverage, as consumers look for everyday products enhanced with functional ingredients that offer more than basic nutrition.

Cannabis brands are increasingly exploring combinations of cannabinoids with vitamins, minerals, and other wellness ingredients to create products that fit into categories beyond traditional cannabis.

Rescheduling has encouraged some cannabis brands to think more like a medical market, developing products that focus on health and therapeutic applications.

Betty’s Bite-A-Mins will be available through MariMed’s Thrive Dispensary locations and other licensed cannabis retailers across Massachusetts, Maryland, Illinois, Delaware, Maine, and Rhode Island.

Betty’s Eddies shows how cannabis brands can expand the category by looking beyond traditional edibles and exploring new product formats.

https://cannabisindustryjournal.com/feature_article/cannabis-gummies-move-into-the-multivitamin-aisle/

u/markoj22 — 4 days ago

Burglars jailed for theft of Mounjaro worth £1m

Mark Harding, Robert Townsend and Peter Costello were sentenced at St Albans Crown Court on Wednesday

Three burglars have been jailed after stealing nearly £1m worth of the weight loss drug Mounjaro from a distribution site.

Mark Harding, 55, Robert Townsend, 59 and Peter Costello, 44, carried out the "highly organised" and "sophisticated" burglary at Phoenix Healthcare Distribution in St Albans, Hertfordshire, on 24 January this year.

Police said the three men had broken into the unit through an air-conditioning duct, with their actions captured on CCTV footage played to St Albans Crown Court.

Judge Jonathan Mann KC said: "I have no doubt in concluding that a great deal of money was made as an effect of the distribution of the Mounjaro."

The haul of weight-loss drugs - worth a total of £944,544 - has still not been found.

Costello and Townsend, both from Sutton, and Harding from Feltham, in south-west London, were all charged with burglary after their arrest on 11 February.

Harding and Townsend also admitted to possession of criminal property after being found with thousands of pounds secreted away in their homes.

About £35,000 in cash was found in a picnic basket in Harding's wardrobe, while £19,900 was found behind an extractor fan in Townsend's home, the court heard.

Hertfordshire Police has previously reminded people that unusually cheap weight loss drugs could be dangerous

CCTV played in court showed Costello and Harding, both clad in black, moving quickly through the site and taking boxes of the drug from a refrigerated area.

The defendants left and returned for more boxes less than two hours later.

The court heard Townsend had stayed outside as a "lookout" and had "scouted out" the site a week earlier.

Prosecuting, Harrie Austin-Jones said "there was advanced targeting and scoping of the building" which meant they knew how to circumvent the alarms.

They also sprayed black paint on some of the CCTV cameras, the court heard.

On behalf of Harding, Graham Logan argued that he "didn't know the full extent of what was involved", and sought to minimise the sophistication of the burglary.

However, Judge Mann said "it belies common sense" that any of them did not know what they were getting themselves into.

'Pre-planned and calculated'

All three defendants had previous convictions, with Costello and Harding both prosecuted for other burglaries in the last decade.

Each was jailed for five years and three months for burglary, with Townsend and Harding receiving nine-month concurrent sentences for the criminal property charge.

Sophia Malik, from the Crown Prosecution Service, said: "This was a carefully planned burglary involving high-value pharmaceutical products.

"The defendants went to significant lengths to avoid being caught, but the evidence gathered through phone location data, automatic number plate recognition records and CCTV clearly linked them with the offences."

Det Sgt Will Daglish, of Hertfordshire Police, said: "This was a very serious crime – weight-loss drugs must be stored correctly and are dangerous if they are not administered in the right way.

"By breaking into the fridges storing the Mounjaro drug, their actions posed a serious health risk to the public.

"This was evidently a pre-planned and calculated burglary, and they will now serve several years behind bars."

https://www.bbc.co.uk/news/articles/ceqde4y4eryo

u/markoj22 — 4 days ago

Measuring What Matters: Why Outcomes Will Decide the Future of Cannabis Medicine

The UK medical cannabis sector has spent seven years arguing for access. The next argument will be settled on outcomes, and judging by the evidence available right now, the industry is not equipped to win it.

The Lancet Psychiatry‘s systematic review of cannabinoids, published on 16 March, concluded that the available randomised controlled trial evidence does not justify the routine prescribing of medical cannabis for mental health disorders. 

Following its publication, the industry has been the target of a relentless media campaign, calling for tighter regulation, increased prescription oversight, and an overarching rethink of the entire sector. 

According to recent figures from NHSBSA FOI data, the number of private prescriptions more than doubled from 283,000 in 2023 to around 659,000 in 2024. 

UK prescriptions have scaled far faster than the clinical evidence base could match. Clinics that focus on keeping meticulous, credible, longitudinal patient data stand at a significant advantage. 

Not only do they have a solid evidence base to defend their prescriptions against such scrutiny, but have the opportunity to build a wider, more substantial case for the benefits so many of their patients experience with treatment. 

The evidence the trials cannot reach

One of the key studies referenced in the Lancet study was the Wilson review, which screened 5,774 studies and included 54 randomised controlled trials covering 2,477 participants. 

It found no significant benefit for anxiety, PTSD, psychotic disorders, OCD, anorexia or opioid use disorder, and no eligible trials at all for depression. 

Evidence certainty was rated very low or low under the GRADE framework, as Business of Cannabis reported at the time of publication. The review does not conclude that cannabinoids don’t work, but that the controlled evidence base is too thin to support routine prescribing at scale, and that the conditions driving prescription growth are precisely those for which trial evidence is weakest.

Dr Anne Schlag of Drug Science, which operates the UK’s largest non-profit medical cannabis registry, has argued that the patients most likely to seek a prescription are typically multi-morbid, sometimes carrying up to ten concurrent diagnoses, and would be excluded from RCT cohorts. 

The registry, now following more than 4,500 patients for up to five years, finds significant symptom reduction at three months in those with comorbid depression and PTSD. 

Uncontrolled data cannot, on its own, establish whether a treatment works. The patients’ UK clinics treat patients outside the RCT base, and finding a solution to this dynamic is now the critical problem for the industry to solve.

READ MORE…

What 1,669 patients told one clinic

In November 2025, Releaf, a CQC-regulated medical cannabis clinic and one of the UK’s largest, surveyed its active patient base. 

Of 1,669 respondents, 672 reported being prescribed for anxiety, depression, PTSD or a combination of the three. Participation was voluntary and uncompensated.

Writing in Releaf’s own blog, Sam North said the survey returned ‘a very consistent signal across all three conditions’. 

Among the mental health cohort, 80% rated their treatment very or extremely effective and 94% reported at least moderate effectiveness. 

Meanwhile, fewer than 4% reported limited or no effect. Improved quality of life was reported by 98%, improved daily functioning by 87%, and improved capacity for work or study by just under 70%. PTSD respondents reported the strongest overall response.

Survey data of this kind cannot do what an RCT does, the respondent pool is self-selecting and paying privately. Outcomes are self-reported, and there is no control arm. 

Releaf’s findings sit broadly in line with two recent peer-reviewed cohorts. A two-year case series of 698 depression patients drawn from the UK Medical Cannabis Registry, published in the Journal of Affective Disorders, found significant reductions in depression severity at one, three, six, 12 and 24 months. 

A December 2025 prospective cohort also found that patients above clinical thresholds fell from 81% (anxiety) and 76% (depression) at baseline to below 50% within three months.

The data that the system cannot see

In October 2025, Business of Cannabis analysed NHSBSA records covering more than 132,000 prescription entries. The agency confirmed that private cannabis prescriptions are ‘manually recorded from often handwritten prescriptions’ with ‘no standardised naming convention’. Product match rates fell as low as 77.5% for 2022, meaning nearly one in four prescription records that year could not be reliably assigned to a specific medicine.

That same fractured dataset underpins the figures now driving mainstream coverage. The Times‘ April investigation, which claimed ten doctors issued more than half of all UK cannabis prescriptions since 2019, drew on a bespoke FOI response that has not been published in full. 

Business of Cannabis has requested this same data, and will report it publicly once it has been received. 

This data issue cuts both ways. Critics work from a dataset that cannot reliably account for what each clinic does, and operators defend themselves without the outcomes record that would settle the question.

Oliver’s Law, launched by Oliver Robinson’s family, calls for a central NHS registry recording every prescription issued, alongside routine CQC inspections and published prescribing data. 

Many in the industry have argued for the same architecture for years. The reform climate has made it close to inevitable. The question is whether the registry is designed collaboratively, with the operators that hold the patient relationships, or imposed by a regulator working without them.

The next test

The CQC and MHRA already have the powers required to implement these changes and establish a sector-wide requirement to capture and publish standardised outcome measures, using validated instruments, at agreed follow-up intervals. 

Such a mandate would supply the longitudinal evidence the trial pathway cannot generate at scale, give regulators a defensible mechanism for distinguishing well-run clinics from poorly run ones, and give the sector the response it currently lacks when challenged on safety, scale or efficacy.

Whether a top-down mandated change is pushed through by regulators first, or whether the industry itself pulls together to produce a coordinated industry standard, those who are already building this evidence base will have a seat at the table whenever change is made. 

https://businessofcannabis.com/measuring-what-matters-why-outcomes-will-decide-the-future-of-cannabis-medicine/

reddit.com
u/markoj22 — 4 days ago

“You Have To Be Careful”: 24 Candid GLP-1 Stories About The Good, The Bad, And The Unexpected Side-Effects Of Weight Loss Drugs

“I’m the one that has to live in my body, I’m doing what I need to get my life back, and that’s all that matters.”

  • Originally developed to treat Type 2 diabetes, GLP-1 medications like Ozempic, Wegovy, and Mounjaro are now widely prescribed for weight loss. They've become so mainstream that it feels like everyone falls into one of three categories: you're either taking one yourself, know someone who is, or can't open your phone without seeing someone talk about them.

While these types of medication have been life-changing for many, they can also bring on a variety of side effects. Over the past few months, we've been sharing firsthand stories from people taking GLP-1 medications, and there's been no shortage of thoughtful, honest insights. So, we asked for even more responses — and once again, people delivered. Here are 24 things people wish they had known before starting their GLP-1 journeys:

1. "The only weird side effect I have is that most potatoes taste rotten. Baked, mashed, and French fries...all gross. Only Waffle House hashbrowns and tater tots are passable. I miss potatoes."

Caterina Oltean / 500px / Getty Images/500px Prime

—Anonymous, F, 50, MD

2. "I have been taking Zepbound for 1.5 years and have lost 100 pounds, but I did not anticipate the amount of hair loss I'd experience on the meds. Not necessarily balding spots, but a significant loss in hair density."

—Anonymous, 42, F, MD

3. "I am one of the very rare people who are highly allergic to GLP-1s! I was on a low dose for a few months and was feeling fine. When I went up in dose, I started feeling exhausted, and a few weeks later, it got to the point where I was sleeping almost the entire day! Turns out my liver was starting to fail because of the meds. Took a few months to get healthy after I stopped taking it. I would love to be able to use GLP-1s to lose weight, but I'm stuck with the old-fashioned way!"

—Anonymous, 36, F, USA

4. "I was on semaglutide for a year and had horrible diarrhea and vomiting, and only lost about 9 pounds. I have been on tirzepetide for about 7 months and have still only lost about 10 pounds. Fewer GI side effects, but I have injection site inflammation and irritation. My main complaint is I'm just not seeing the results everyone else seems to see. Not sure if it's because I honestly never really ate that many calories to begin with, but I just don't eat particularly healthy food. It's frustrating to hear about people losing 40-50 pounds, and I am barely seeing the scale move week to week."

Olga Rolenko / Getty Images

—Anonymous, 44, F, MN

5. "So important to drink WATER while taking these meds! I had severe constipation (did not read the directions correctly, duh), and my friend said she was drinking two to three liters of water daily, yup, read the directions again...that is what should be done. Fiber also helps so much."

—Anonymous, 54, F, Sweden

6. "I was on Saxenda and developed diverticulitis. I had to take antibiotics to cure it. I stopped that med, then switched to Wegovy for 9 months, and lost no weight. I then went on Zepbound. It ruined my eyesight, and I ended up with a hole in my retina. I had to have eye surgery, and it was awful. The doctor says my vision will never be 100% again, and I have only lost 7 pounds. These medications are not without side effects. You have to be careful."

—Anonymous, 63, F

7. "No one told me you're not supposed to take Ozempic if you have diabetic retinopathy or diabetic macular edema, both of which can cause blindness on their own. Ozempic makes them worse. I nearly went blind in one eye. I stopped taking Ozempic over two years ago, and I'm still having some issues with that eye, although my vision did clear up after about 8 months. And for all that, I didn't lose weight, and my labs didn't change. The only thing that helped me was bariatric surgery."

Fotografía De ELuVe / Getty Images

—Anonymous, 41, F, USA

8. "If you're on GLP-1s, make sure you are also taking some form of laxative to help regulate your bowels!!! Very important. You will thank me if you have had impacted stools that required a hospital visit."

—Anonymous, 55, F, Atlanta, GA

9. "I was on several different GLP-1s for two years, and the entire time I only lost about 35 pounds. I have a nerve disorder, PMOS (PCOS), pelvic floor dysfunction, thyroid disease…the list goes on. But those comorbid conditions made losing weight more difficult. My OBGYN started me on the medication, and I quickly started losing the weight, but I would vomit uncontrollably to the point that my ribs would be sore, my eyes would be bloodshot, and my face would be bruised from heaving so hard."

"The longest I went without a bowel movement was 8 days, and I was then diagnosed with gastroparesis, severe chronic gastritis, and bleeding of the bowel. I finally stopped the meds when my dentist told me that if I didn’t stop the vomiting, I would lose all my teeth by 30. My gastrointestinal issues are permanent now."

Javier Zayas Photography / Getty Images

—Anonymous, 21, F, USA

10. "I was on Ozempic to help with diabetes. I developed gastroparesis. I was nauseous constantly. I vomited daily and had liquid diarrhea daily. I lost two pant sizes in a short time. But I was malnourished despite still being obese. Even the thought of food made me sick. I'm not able to properly digest the healthy foods I like and should eat. I’m on the toilet within a short time, and the food is in the toilet. Foods that are not good for diabetics are what I can tolerate — bread and pasta. I miss salads, broccoli, beans, carrots, and apples. I had several tests done to verify gastroparesis."

"Didn’t know it was possible to be constipated and have diarrhea at the same time. Even if I watch what I eat, I have several flare-ups, stomach pain, and diarrhea weekly. I lost my health insurance and can’t afford Ozempic without it. I still have issues due to gastroparesis. I’d rather vomit than have diarrhea. My doctor that prescribed Ozempic, glossed over the possible side effect of delayed digestion. He did not explain what that fully means, the details and results of that."

—Anonymous

11. "Permanent gastroparesis, or stomach paralysis. I was pushed by my doctor to start a GLP-1 despite my concerns. I took the starter dose of Victoza for two months before everything went on backorder, and it wasn't available anymore. Yes, it took away my hunger, but only by paralyzing my stomach. The doctor said it was temporary; it's been over three years. I can't eat anything without pain, and I feel uncomfortably full 24/7. I had a supervised three-day fast and stayed full the entire time. I've started having hypoglycemic episodes because I'm so full and don't eat. The kicker is that my endocrinologist recommended a GLP-1 to treat my hypoglycemia. Doctors are starting to bully patients into taking one. I wish I never did."

—Anonymous, 33, F, USA

12. "I started on Trulicity; it did nothing but cause stomach issues, so I switched to Ozempic, and the stomach issues worked themselves out. But I began burping constantly. I switched to Zepbound two months ago, and the burping has only gotten worse. I haven't had sulfur burps once; just normal burps constantly, sometimes deep and very loud. It is very annoying for me, and I'm sure for my husband too. I am certain he wishes I would stop saying 'Excuse me' after every single burp, because he's started telling me he is done excusing me for the day. But I have lost around 50 pounds over the past year, making the burps tolerable."

M-gucci / Getty Images

—Anonymous, 49, F, MO, USA

13. "My brain is quiet for the first time! No food noise, no compulsive thoughts. I’m more organized, I get shit done, and I became incredibly aware that I may have ADHD. I’ve been on Ozempic for three months, and it was a decision to help with chronic pain. I’ve lost 35 pounds, with minimal side effects aside from being dehydrated so badly that my muscles keep cramping, and my body is achy. But I drink way more water and Gatorade now, my pain meds have started to decrease, and it’s changed my life! I used to feel ashamed and embarrassed for taking these meds, but I don’t care anymore. I’m the one that has to live in my body, I’m doing what I need to get my life back, and that’s all that matters."

—Anonymous, 38, F, Canada

14. "After losing 18 pounds in two months on my own, I started Zepbound, and the weight just started falling off. But the first several weeks were miserable. The worst side effects were the nausea and my ADHD medication not working. I changed my injection site from my stomach to my thigh, and it helped the nausea tremendously. In total, I’m down 40 pounds in 6 months! I’m starting to wean off of it and am looking into therapy to help reexamine my relationship to food and weight loss. There are days when I’m eating so little, I am worried about developing an eating disorder when I don’t have the medication, and I want to remain healthy."

—Anonymous, 30, F, NY

15. "Holy shit, the hair loss! I was only on it for four months. Lost 33 pounds, but by month three, I was losing handfuls of hair all the time. It finally stopped three months after going off the medication. I was told I would lose 'some' hair, but I had to buy a hair topper, it was so bad. Also, it made me very sleepy. How do I work out if I want to sleep all the time?"

—Anonymous, 44, F, Las Vegas, NV

16. "I got mine through an online pharmacy, and although I had had gallstones before, I skipped that question on the online screening questionnaire. The medication then gave me pancreatitis and gallstones so bad that I was in the hospital. Felt like my stomach would explode. Had to stop the meds. I've had to lose weight the old-fashioned way now — calorie cutting and exercising."

—Anonymous, 44, F, UK

17. "I wish someone had told me it can completely play havoc on your nervous system AND the big one — I ended up having to have my gallbladder removed as it caused mine to become inflamed, so incredibly painful, and diseased. I was only microdosing for a few months, and even that caused complete chaos."

—Anonymous, 43, F, Maine

18. "You have to learn how to manage the roller coaster. First three days after the shot, expect constipation. Take a stool softener. If you’re nauseous, you ate too much. So many people are prescribed this medication with zero nutritional backup. Gotta hit 90 grams of protein every day. Shakes, protein water, etc. Fiber: 25 grams, so take a fiber pill. Eventually, this levels out. Fatty food is a disaster; just don’t eat it. Diarrhea will be the answer. It hits hard. Fatigue is usually due to not eating enough calories. Also, it can feel like depression. Brain fog happens when you aren't eating enough carbs. This is to reset your relationship with food. You end up eating what your body needs, not what you’re craving. There are no cravings. Muscle mass is important for many reasons, not just to avoid Ozempic butt. Remember, your heart is a muscle. If everything is getting flabby, so is your heart."

greenovercoat48

19. "I took Semaglutide from an online service for about 10 weeks. I lost only one pound in that time, but the elimination of cravings and food noise between meals was wonderful. The improvement in focus I gained from not being hungry all the time was a plus, for a time. But I stopped last week because the medication caused malaise, fatigue, and muscle weakness. Before the meds, I'd been swimming 3 to 5 mornings a week for several years. But after 6 to 7 weeks on the meds, I could not drag myself out of bed in the mornings. When I was able to get up and go to the pool, my muscles were exhausted after doing half the laps I'd been doing before. A 30-minute walk at lunchtime felt like torture. I attempted to get energy by drinking more coffee, but the drug seemed to make coffee taste terrible. I hoped the fatigue would subside, but it only got worse over the weeks. Now I know why people lose muscle and bone mass when they take these drugs."

sharethebuzz

20. "I’m on 15mg of Mounjaro, and the only bad side effect is I can’t lose weight without logging in my food to MyFitnessPal and maintaining a 1500-calorie-a-day diet. The pounds didn’t 'melt away' magically. The best effect is that I went from a 7.1 to a 6.2 A1C. I will say it is easier to diet with Mounjaro due to a reduction in food noise, but it would be easy for me to overeat without the accountability of logging everything in."

D3sign / Getty Images

busdrivermike

21. "My dad has been using one of these medications, and it has literally saved his life. All his labs are good, his blood pressure is normal, he can walk without pain, he is creating art again, his humor is back, and he is the dad I remember from childhood. One of the biggest things is that he no longer craves fast food. He can't even stand the smell of it anymore. He has had only minor side effects, and those were addressed. My mom has been taking the meds too and hasn't noticed any weight loss, but her blood sugar is better. She has been having some possible side effects: exhaustion, dizziness, weakness in her limbs, and confusion. It's unclear at this point if those are due to the medication or some other underlying issues."

ehch

22. "As someone who has taken GLP-1s to lose weight and now has a better understanding of what my body needs in order to be healthy, I actually started craving fruit and vegetables over processed junk. It’s sad that this country would rather make drugs to help people lose weight, rather than make food better for us. They’re literally working to make food more addictive to bypass the effects of GLP-1s. The goal IS to keep you unhealthy. I don’t judge anyone who feels like they need to take this drug; I judge the people at the very top who created this situation in the first place."

Witthaya Prasongsin / Getty Images

dgreat42

23. "I've been on Mounjaro for almost two years and have lost the 70 pounds that were my target loss. I've also gone from 6.3 A1C to 5.2. I'm THRILLED. I've also gotten the sulfur burps, which I wasn't warned about. They are RAMPANT two to three days after my dose. But I'm mentally an adolescent, so I'm more entertained by them. The constipation I was warned about, and as someone with IBS-D, it's been a bit of a tap dance to make sure I'm not having intense pain. My doctor told me to drink Miralax or a similar product once a week, and now I have no more issues. Your mileage may vary, but for me it's been great."

katet4dbf41478

24. And finally, "I haven’t seen anyone else say anything about this yet, but I take a semaglutide compound, and in addition to quieting food noise, stopping blood sugar spikes, and losing weight, my perimenopause symptoms also became almost nonexistent. Some night sweats and hot flashes, but that was pretty much it. I credit the meds."

https://www.buzzfeed.com/lily_grossinger/glp1-side-effects-july-2026

reddit.com
u/markoj22 — 4 days ago